FibroGen Inc. (NASDAQ:FGEN) saw a downside of -3.93% to $1.84 after subtracting -$0.07 on Monday. The 5-day average trading volume is 1,592,789 shares of the company’s common stock. It has gained $2.0750 in the past week and touched a new high 1 time within the past 5 days. An average of 2,882,632 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,303,215.
FGEN’s 1-month performance is -32.04% or -$0.8599 on its low of $1.8200 reached on 07/28/23. The company’s shares have touched a 52-week low of $1.82 and high of $25.69, with the stock’s rally to the 52-week high happening on 02/03/23. YTD, FGEN has lost -88.55% or -$14.1799 and has reached a new high 10 times. However, the current price is down -92.86% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
FGEN stock investors last saw insider trading activity on Jul 11.Henderson Jeffrey William (Director) most recently sold 2,000 shares at $2.69 per share on Jul 11. This transaction cost the insider $5,380. Chief Executive Officer, Conterno Enrique A, sold 1,880 shares at a price of $2.80 on Jul 07. Then, on Jun 23, Chief Commercial Officer Wettig Thane sold 791 shares at a price of $16.53 per share. This transaction amounted to $13,075.
Valuation Metrics
FGEN stock has a beta of 0.48. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.52.
FibroGen Inc.’s quick ratio for the period ended March 30 was 1.50, with the current ratio over the same period at 1.70. In terms of profitability, the gross margin trailing 12 months is 83.20%. The trailing 12-month EBITDA margin is -206.36%. The firm’s gross profit as reported stood at $120.45 million against revenue of $140.73 million.
Earnings Surprise
For the quarterly period ending March 30 this year, FibroGen Inc.’s cash and short-term investments amounted to $167.4 million against total debt of $104.09 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 17.6% to -$76.71 million, while revenue of -$66.18 million was 13.73% off the previous quarter. Analysts expected FGEN to announce -$0.75 per share in earnings in its latest quarter, but it posted -$0.81, representing a -8.00% surprise. EBITDA for the quarter stood at more than -$73.81 million. FGEN stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 567.43 million, with total debt at $104.09 million. Shareholders hold equity totaling $97.58 million.
Let’s look briefly at FibroGen Inc. (FGEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 18.85% to suggest the stock is trending oversold, with historical volatility in this time period at 63.37%.
The stock’s 5-day moving average is $1.9060, reflecting a -10.67% or -$0.2199 change from its current price. FGEN is currently trading -34.05% above its 20-day SMA, -90.83% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -89.16% and SMA200 by-89.41%.
Stochastic %K and %D was 6.40% and 8.65% and the average true range (ATR) pointed at 0.2000. The RSI (14) points at 17.33%, while the 14-day stochastic is at 2.64% with the period’s ATR at 0.3448. The stock’s 9-day MACD Oscillator is pointing at -0.0366 and -0.1219 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for FibroGen Inc. (NASDAQ: FGEN), William Blair downgraded it to a Mkt perform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for FGEN stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate FGEN as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is FGEN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.00 and a high of $37.20, with their median price target at $20.00. Looking at these predictions, the average price target given by analysts is for FibroGen Inc. (FGEN) stock is $20.04.
